Show simple item record

dc.contributor.authorCooksley, Timothy J
dc.contributor.authorGirotra, M.
dc.contributor.authorGinex, P.
dc.contributor.authorGordon, R. A.
dc.contributor.authorAnderson, R.
dc.contributor.authorBlidner, A.
dc.contributor.authorChoi, J.
dc.contributor.authorDougan, M.
dc.contributor.authorGlezerman, I.
dc.contributor.authorGupta, D.
dc.contributor.authorJohnson, D.
dc.contributor.authorShannon, V. R.
dc.contributor.authorSuarez-Almazor, M.
dc.contributor.authorRapoport, B. L.
dc.date.accessioned2020-09-16T11:57:54Z
dc.date.available2020-09-16T11:57:54Z
dc.date.issued2020en
dc.identifier.citationCooksley T, Girotra M, Ginex P, Gordon RA, Anderson R, Blidner A, et al. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune checkpoint inhibitor endocrinopathies and the role of advanced practice providers in the management of immune-mediated toxicities. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2020.en
dc.identifier.pmid32856213en
dc.identifier.doi10.1007/s00520-020-05709-1en
dc.identifier.urihttp://hdl.handle.net/10541/623236
dc.description.abstractImmune checkpoint inhibitors (ICIs) have emerged as the newest pillar of cancer treatment, transforming outcomes in melanoma and showing benefit in a range of malignancies. Immune-mediated toxicities, stemming from increased activity within the T cell lineage, range from asymptomatic or mild complications to those that are fulminant and potentially fatal. Immune-mediated endocrinopathies include hypophysitis, thyroiditis, and insulin-dependent diabetes mellitus. These presentations, which may be vague and non-specific, can be life-threatening if not diagnosed and treated appropriately. This review considers the work-up and management of immune-mediated endocrinopathies and also considers the role of advanced practice practitioners in the management of immune-mediated toxicities. These state-of-the-art MASCC recommendations represent a comprehensive overview of the management and clinical work-up in those in whom the diagnosis should be considered.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1007/s00520-020-05709-1en
dc.titleMultinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune checkpoint inhibitor endocrinopathies and the role of advanced practice providers in the management of immune-mediated toxicitiesen
dc.typeArticleen
dc.contributor.departmentThe Christie and Manchester University Foundation Trust, Manchester, UK.en
dc.identifier.journalSupportive Care in Canceren
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record